Acute promyelocytic leukemia: Difference between revisions
No edit summary |
No edit summary |
||
| Line 16: | Line 16: | ||
'''For patient information click [[Leukemia (patient information)|here]]''' | '''For patient information click [[Leukemia (patient information)|here]]''' | ||
{{CMG}}; {{GRR}} {{Nat}} | {{CMG}}; {{AE}} {{S.G.}} {{GRR}} {{Nat}} | ||
{{SK}} Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant | {{SK}} Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant | ||
Latest revision as of 14:31, 29 October 2019
Template:DiseaseDisorder infobox
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2] Grammar Reviewer: Natalie Harpenau, B.S.[3]
Synonyms and keywords: Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Acute promyelocytic leukemia from Other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Other Imaging studies | Other Diagnostic Studies
Treatment
Medical Therapy | Cost-Effectiveness of Therapy | Future or Investigational Therapies